Spots Global Cancer Trial Database for Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

Official Title: Phase I Trial of Cisplatin and Pemetrexed in Combination With Panobinostat in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer

Study ID: NCT01336842

Conditions

Solid Tumors

Non-Small Cell Lung Cancer (NSCLC)

Interventions

Panobinostat, Cisplatin, Pemetrexed

Study Description

Brief Summary: The purpose of this study is to find out if panobinostat taken with cisplatin and pemetrexed can be used safely without increasing side effects and that the combination will have a better effect than platinum-based doublet chemotherapy alone.

Detailed Description: The purpose of this phase I study of oral panobinostat plus cisplatin and pemetrexed is to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) in patients with advanced solid tumors, with an emphasis in non-small cell lung cancer. Another purpose of this study is to find out if oral panobinostat in combination with cisplatin and pemetrexed can be administered safely without significant increase in toxicity and that the combination will increase efficacy compared to platinum-based doublet chemotherapy alone.